AUTOIMMUNE THYROIDITIS · CHRONIC LYMPHOCYTIC THYROIDITIS · HASHIMOTO'S ENCEPHALOPATHY
A physician-led, laboratory-verified treatment programme designed to reduce thyroid autoimmunity, restore hormonal balance and improve systemic well-being — tailored to the individual immunological profile, disease stage and clinical needs of each patient.
Request Medical ConsultationAbout the Condition
Hashimoto's thyroiditis is a chronic autoimmune disorder in which the immune system produces antibodies (anti-TPO, anti-thyroglobulin) that progressively attack and destroy thyroid follicular cells. Over time, this lymphocytic infiltration leads to gradual loss of thyroid tissue and declining hormone production.
The condition is the most common cause of hypothyroidism in iodine-sufficient regions, affecting roughly 5% of the adult population — with a strong female predominance (approximately 8:1 female-to-male ratio). Many patients experience years of fluctuating thyroid function before reaching overt hypothyroidism.
Standard management relies on lifelong levothyroxine replacement, which addresses hormone deficiency but does not modify the underlying autoimmune process. The immune attack on the thyroid continues unchecked — which is the specific mechanism our programme targets.
Classic Hashimoto's (Gradual Hypothyroidism)
The most common presentation. Thyroid function declines gradually over months to years as lymphocytic infiltration destroys follicular tissue. Patients typically present with fatigue, weight gain, cold intolerance and cognitive slowing. Anti-TPO titres are persistently elevated. Progression to overt hypothyroidism is the expected course without intervention.
Hashitoxicosis (Transient Hyperthyroid Phase)
Occurs when destruction of thyroid follicles releases stored hormones into the bloodstream, producing temporary hyperthyroid symptoms — palpitations, anxiety, tremor, heat intolerance. This phase may be misdiagnosed as Graves' disease. It is self-limiting and typically followed by a shift toward hypothyroidism. Approximately 5–10% of Hashimoto's patients experience this phase.
Hashimoto's Encephalopathy (SREAT)
A rare neurological variant associated with high anti-thyroid antibody titres and CNS inflammation. Presents with cognitive decline, seizures, myoclonus, psychosis or stroke-like episodes — often independent of thyroid hormone levels. Steroid-responsive, but frequently misdiagnosed. Requires immunomodulatory intervention beyond standard thyroid hormone replacement.
Painless Thyroiditis Variant
A subacute form presenting with mild thyrotoxicosis followed by transient hypothyroidism, often postpartum. Thyroid is non-tender, distinguishing it from subacute granulomatous thyroiditis. Recovery of normal thyroid function occurs in many cases, but a proportion of patients progress to permanent hypothyroidism with persistently elevated antibodies.
Our program is individually adapted for all subtypes and all stages of progression.
Important: Each patient is accepted into the programme only after a comprehensive individual medical assessment, which evaluates diagnosis, antibody levels, thyroid function history, comorbidities and overall clinical profile.
Clinical Outcomes
The following data are derived from structured observational analysis of patients treated at BioCells Medical between 2017 and 2025. All figures represent aggregated clinical registry outcomes with longitudinal follow-up. These are observational results — not randomised controlled trial data — and do not constitute a guarantee of therapeutic effect.
30
Hashimoto’s patients treated since 2013
74%
measurable functional stabilisation on anti-TPO at 3–6 months
−48%
average anti-TPO score change at 6 months — vs. expected +6% natural progression
58%
sustained functional stability with average 1.5 years of follow-up
82%
showed improvement in one or more measured domains
75%
retained independence in basic activities of daily living (ADL) at 12 months
Joint/organ function (levothyroxine dose reduction, TSH normalisation, thyroid function stability)
70%
Inflammation (anti-TPO/anti-Tg antibody reduction, thyroid imaging findings)
74%
Systemic symptoms (chronic fatigue, brain fog, weight stability, joint and muscle pain)
80%
Quality of life (mood stability, cognitive clarity, daily energy)
72%
2–6 weeks
Initial clinical response
2–5 months
Clinically meaningful change
1–2 years onward
Long-term stability — continuous monitoring
Important: Outcomes depend on disease duration, baseline antibody levels, degree of existing thyroid tissue loss and individual immunological response. Patients with long-standing overt hypothyroidism and complete thyroid atrophy may experience more limited antibody reduction.
Find out if our program can help in your specific case. The initial medical consultation is free and carries no obligation.
Request ConsultationThe BioCells Program
Our Hashimoto's programme combines five biological components into a single personalised protocol. No two protocols are identical — each is constructed following a detailed medical evaluation of the patient's immunological profile, thyroid status and clinical priorities.
Minimally invasive administration
Treatment is delivered by intravenous infusion — not surgical instruments. No thyroidectomy risk, no scarring.
No general anaesthesia
The entire procedure is performed under standard clinical conditions without sedation or anaesthetic risk.
No risk of immune rejection
MSCs are immunoprivileged: they express low levels of HLA-I, lack HLA-II and carry a minimal risk of rejection whether the protocol is autologous or allogeneic. Allogeneic MSC protocols do not require immunosuppression.
Targets the autoimmune mechanism, not just hormone levels
Standard levothyroxine replacement addresses the hormonal consequence of thyroid destruction but does nothing to stop the immune attack. Our protocol targets the immunological process itself — antibody production, lymphocytic infiltration, Th1/Th17 imbalance.
Complements existing medication
Our programme is compatible with levothyroxine and other current thyroid medications. Patients do not need to discontinue existing treatment before commencing our protocol.
Patients from around the world
We work with patients from around the world. Airport transfers, accommodation, visa support and multilingual coordination are included in every treatment programme.
What It Is
MSCs are multipotent regenerative cells with established immunomodulatory and tissue-protective properties. In autoimmune thyroiditis, their primary role is to recalibrate the immune response that drives thyroid follicular destruction.
How It Is Done
Cells are collected from the patient's own bone marrow (autologous, approximately 3-5 ml under local anaesthesia) or sourced from a certified donor (allogeneic), depending on individual clinical indications. All cells are expanded, quality-controlled and tested in our certified Warsaw laboratory before administration.
Biological Mechanisms
How This Helps in Hashimoto's Thyroiditis
In Hashimoto's, the immune system chronically attacks thyroid tissue through antibody-mediated and cell-mediated pathways. MSCs modulate this process by shifting the immune environment away from destructive Th1/Th17 dominance toward regulatory tolerance — reducing ongoing tissue damage and creating conditions for functional stabilisation.
Your Medical Board
The exact combination, dosage, sequencing and delivery method of all five components is determined individually by our medical board for each patient. No two treatment protocols are identical. Your programme is constructed based on your specific diagnosis, antibody profile, thyroid function history, immune markers and clinical priorities.
Your protocol is designed individually. Speak with our medical team to understand what your personalised program would include.
Request ConsultationPatient Journey
Your case is reviewed remotely by our physician team. We assess your diagnosis, current antibody levels, thyroid function history and treatment goals. This consultation is free and carries no obligation.
A detailed review of all medical documentation — including thyroid ultrasound, antibody panels, hormone levels and immune markers. Our medical board evaluates eligibility, confirms safety parameters and designs your personalised therapeutic protocol.
Your cells are collected, isolated, expanded and quality-tested in our certified Warsaw laboratory. Each batch receives a full traceability certificate. This stage typically takes 2–3 weeks.
Cells are delivered by intravenous infusion — no surgery, no general anaesthesia. Airport transfers, accommodation and visa support are included in the programme for international patients.
Structured follow-up sessions with our specialist, including repeat antibody testing and thyroid function monitoring. Available at our clinic or remotely coordinated with your local endocrinologist.
Your dedicated coordinator monitors antibody trends, thyroid function and overall well-being. A medical-grade wearable bracelet supports continuous health tracking regardless of your location. Levothyroxine dosage adjustments are coordinated with your treating physician.
The first step is free. Request a medical consultation and our medical consultant will contact you within 24 hours.
Request ConsultationSafety Profile
Cellular therapy is considered safe when delivered under proper medical supervision and according to validated protocols. In our practice, the procedure is well-tolerated by the majority of autoimmune thyroiditis patients.
Temporary mild reactions — such as transient local discomfort at the infusion site, slight fatigue or low-grade temperature — may occur in a minority of patients. These are typically short-lived and indicate active immune engagement.
A final medical assessment is performed on-site before every treatment session. If a patient's status has changed — including acute thyrotoxic episode or intercurrent illness — the programme may be temporarily modified or postponed for safety reasons.
All contraindications are evaluated individually. A contraindication in one clinical context does not necessarily preclude treatment in a different context — this is always determined by physician assessment.
Standard Contraindications
Active acute infection or fever
Active malignancy or ongoing chemotherapy / radiotherapy
Severe decompensated cardiac or renal failure
Pregnancy
Post-Treatment
Dedicated endocrine specialist
monitors antibody levels, thyroid function and systemic symptom progression
Personalised medication adjustment plan
levothyroxine dosage reviewed in coordination with your treating physician as thyroid function changes
Medical-grade wearable monitoring
continuous physiological data collection supporting clinical decision-making
Long-term coordinator support
proactive check-ins, clinical guidance and response to any changes in status
Continued clinical access
our medical team remains available for ongoing reassessment and protocol adjustment
Immunological remodelling is a gradual process. Antibody titres typically decline over weeks to months, and thyroid function adjustments require careful longitudinal monitoring. The period following treatment is as medically important as the treatment itself.
Patient Stories
“The brain fog was the thing that scared me most. I couldn't finish a sentence some days, couldn't remember what I walked into a room for. That started lifting within a few weeks after treatment. My endocrinologist in Milan ran the antibody panel again and was genuinely surprised by the drop. He reduced my medication dose twice since then.”
Patient
Hashimoto's thyroiditis · Italy
Every case is assessed individually by our physician team. Request a consultation to discuss your specific situation with our physician team.
Request ConsultationPatient Cases
Documented treatment outcomes recorded by the BioCells Medical team after personalised regenerative medicine protocols.
Get Started
If you have been diagnosed with Hashimoto's thyroiditis and standard hormone replacement is not adequately controlling your symptoms or antibody levels, our medical team is available for a free, no-obligation medical consultation — based on your diagnosis, immune profile and individual clinical situation.
We review every inquiry personally. You will speak with a physician, not an administrator.
Submit your case online or by phone
Our medical consultant contacts you to review your documents
The medical board presents your personalised treatment plan
Request a Consultation
Tell us about your condition. Our medical consultant will contact you within 24 hours to review your documents.
Open Consultation FormMultilingual coordination — English, Italian, French, Russian, Polish
Evidence Base
Our clinical approach is informed by and consistent with published research in the field of regenerative medicine.
